According to the Zhitong Finance App, Ruibo Bio-B (06938) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 420 million (same unit), an increase of 304.32% over the previous year; profit attributable to the owners of the parent company was 203.01 million yuan, which turned a year-on-year loss into a profit; profit per share was 0.12 yuan.

According to the announcement, the increase in revenue was mainly due to the development and commercialization of small interfering RNA (siRNA) therapy for steatohepatitis (MASH) associated with metabolic dysfunction, partial confirmation of authorized revenue under the exclusive global licensing cooperation between the Group and Madrigal, and revenue confirmed by the Group's cooperation with Boehringer Ingelheim in reaching milestones, which were the core drivers of the Group's revenue growth during the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.